Vanguard Capital Management
PTGX icon

Vanguard Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Vanguard Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$350M Buy
2,853,394
+47,498
+2% +$4.96M 0.01% 839
2026
Q1 		$296M Buy
+2,805,896
New +$248M 0.01% 855

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM

Vanguard Capital Management's PTGX Position: Q2 2026 in Review

Vanguard Capital Management increased its Protagonist Therapeutics (PTGX) stake by 1.7% in Q2 2026, buying an estimated $4.96M and bringing the position to 2,853,394 shares worth $350M. The position accounts for 0.01% of the portfolio, ranked #839.

Vanguard Capital Management first reported a position in PTGX in Q1 2026 and has held it in 2 quarters since. 316 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Vanguard Capital Management held 2,853,394 shares of Protagonist Therapeutics worth $350M as of Q2 2026.
  • Vanguard Capital Management bought 47,498 Protagonist Therapeutics shares in Q2 2026, an estimated $4.96M.
  • Protagonist Therapeutics made up 0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #839 holding.
  • Vanguard Capital Management first reported a position in Protagonist Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.